Infectious disease
It was yet another busy week for clinical trial announcements. Take a look.
The FDA and Regeneron are reportedly in talks to set up an advisory committee meeting to discuss the BLA ahead of the target action date.
Merck is getting its chance at participating in the pandemic. The FDA has announced an outside expert panel will meet on November 30 to deliberate on Merck’s COVID-19 pill.
The news of a unanimous decision by the adcom came just two days after the agency issued a 45-page document that contained vague comments on the drug.
As the FDA prepares to discuss booster shots for Moderna and J&J vaccines, a new study came out suggesting that mixing and matching vaccines works well and is safe.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Research on the ever-evolving SARS-CoV-2 virus continues as scientists scramble to make sense of it and find cures. Here’s a look.
The FDA said that there had been concerns over the reduced effectiveness of the Moderna COVID-19 vaccine against symptomatic disease.
It’s not the COVID-19 vaccine that will get you. The real cause for concern is the virus, and it lies in the fact that both male and female reproductive organs contain cell receptors the virus targets.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.
PRESS RELEASES